Reaction
Myelitis Transverse reporting signals
As of the last recalculation, Myelitis Transverse appears in 1,391 FAERS reports alongside 29 co-occurring drug terms. The strongest observed disproportionality signal is THIOTEPA (PRR 31.8).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Thiotepa | 20 | 31.8 | 31.8 |
| Bupivacaine | 12 | 19.4 | 19.4 |
| Axicabtagene Ciloleucel | 12 | 18.3 | 18.4 |
| Efavirenz | 11 | 14.9 | 14.9 |
| Interferon Beta-1B | 17 | 13.4 | 13.4 |
| Adalimumab-Aaty | 37 | 12.0 | 12.0 |
| Adalimumab-Fkjp | 36 | 11.9 | 11.9 |
| Durvalumab | 16 | 11.9 | 11.9 |
| Chlorthalidone | 9 | 11.7 | 11.7 |
| Itraconazole | 9 | 11.6 | 11.6 |
| Busulfan | 12 | 11.5 | 11.5 |
| Adalimumab-Adaz | 37 | 10.8 | 10.8 |
| Gemcitabine | 25 | 9.7 | 9.7 |
| Temozolomide | 13 | 9.3 | 9.3 |
| Melphalan | 14 | 9.3 | 9.3 |
| Tenofovir Disoproxil Fumarate Tablets | 5 | 8.7 | 8.7 |
| Gemcitabine Hydrochloride | 29 | 8.3 | 8.3 |
| Ipilimumab | 23 | 8.1 | 8.1 |
| Fludarabine Phosphate | 20 | 7.7 | 7.7 |
| Fingolimod Hcl | 39 | 6.9 | 6.9 |
| Pembrolizumab | 42 | 6.1 | 6.1 |
| Interferon Beta-1A | 73 | 5.9 | 5.9 |
| Glatiramer Acetate | 23 | 5.8 | 5.8 |
| Atezolizumab | 14 | 5.4 | 5.4 |
| Nivolumab | 29 | 4.6 | 4.6 |
| Dimethyl Fumarate | 35 | 4.3 | 4.3 |
| Natalizumab | 46 | 3.9 | 3.9 |
| Isotretinoin | 12 | 3.7 | 3.7 |
| Guselkumab | 7 | 2.9 | 2.9 |